Free Trial

Protagenic Therapeutics Q1 2024 Earnings Report

Protagenic Therapeutics logo
$0.42 +0.02 (+4.74%)
As of 10:46 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Protagenic Therapeutics EPS Results

Actual EPS
-$0.39
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Protagenic Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Protagenic Therapeutics Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

Protagenic Therapeutics Earnings Headlines

Donald Trump is about to free crypto from its chains …
With Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only set to be released from its constraints … it could be about to explode. Trump has vowed to roll back Biden’s “crusade against crypto” on his first day in office.
See More Protagenic Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Protagenic Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Protagenic Therapeutics and other key companies, straight to your email.

About Protagenic Therapeutics

Protagenic Therapeutics (NASDAQ:PTIX), a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.

View Protagenic Therapeutics Profile

More Earnings Resources from MarketBeat